Clinical-stage biotech company Emyria (ASX:EMD) and psychiatrist-led medical practice PAX Centre have developed a care model for psilocybin-assisted therapy.

The company states this collaboration extension is an addition to its existing MDMA-assisted therapy care model.

Both care models will complement each other as they address the substantial overlap between symptoms of post-traumatic stress disorder (PTSD) and major depression.

“The generalist training provided by Dr. Ben Sessa supports our mission to create innovative and effective mental health care models within community psychiatry”

Similar to the recently developed, MDMA-assisted therapy model, Emyria will develop the clinical delivery and data monitoring protocols, while PAX will provide specialists and trained therapists, and an appropriate facility to administer the therapy safely.

Emyria states that renowned psychiatrist and MDMA researcher, Dr. Ben Sessa will be engaging to provide therapist training across MDMA and psilocybin.

Commenting on the new therapy care model, Emyria Managing Director Michael Winlo said: “The generalist training provided by Dr. Ben Sessa supports our mission to create innovative and effective mental health care models within community psychiatry as well as supports our goal to generate high-quality clinical data.”

In addition, PAX Centre Director and Psychiatrist, Jon Laugharne said: “These co-occurring conditions present unique challenges, and we are hopeful that our collaboration with Emyria and the training support of Dr. Ben Sessa, which will help us provide more comprehensive and evidence-based care for our patients.”

The company states that its team has ‘successfully’ secured a supply of patient-ready MDMA, and the important process has begun.

The care plan has been finalised, with preparations well underway at the facility to accommodate the requirements of MDMA-assisted therapy.

In addition, Emyria states that Dr. Sessa will be providing upcoming training sessions to support and equip the experienced staff with the necessary skills and knowledge to provide the ‘highest’ standard of care.

Elyria is a clinical drug development and care delivery company, focused on expediting drug development and improving patient outcomes in neuroscience and mental health.

The company aims at achieving this through drug development, new drug discoveries, and proprietary real-world data (RWD).